Clinical Trials

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

April 3rd, 2024 | Clinical Trials

NCT Number: NCT05849298 Phase: Trial Summary: The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium [177Lu] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in pa – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Novartis Pharmaceuticals Acronym: PSMACare

Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)

April 3rd, 2024 | Clinical Trials

NCT Number: NCT05882253 Phase: Trial Summary: The researchers hope to learn if specific types of MRI software and techniques can help improve early prostate cancer detection at time of a MRI-guided prostate biopsy. – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): The University of Texas Health Science Center at San Antonio Acronym: IMAGINED

Clinical Trial of Green Tea Catechins in Men on Active Surveillance

February 27th, 2024 | Clinical Trials

NCT Number: NCT04300855 Phase: Phase 2 Trial Summary: This randomized double-blinded Phase II clinical trial will evaluate the bioavailability, safety, effectiveness and validate the mechanism by which a standardized formulation of wh – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Acronym:

Diffusion Basis Spectrum Imaging of the Prostate

February 27th, 2024 | Clinical Trials

NCT Number: NCT04420702 Phase: Not Applicable Trial Summary: Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically si – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Washington University School of Medicine Acronym:

PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2

February 27th, 2024 | Clinical Trials

NCT Number: NCT04815876 Phase: NA Trial Summary: Approximately one million transrectal prostate biopsies are performed annually in the U.S., and the risk of post- biopsy infection is increasing due to greater antibiotic resistanc – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College of Cornell University Acronym: PREVENT2

Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer

February 27th, 2024 | Clinical Trials

NCT Number: NCT04984343 Phase: Phase 2 Trial Summary: The study is a randomized study that compares 5 radiation therapy treatments to 2 radiation therapy treatments in men with lo – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College of Cornell University Acronym: FORT

MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)

February 27th, 2024 | Clinical Trials

NCT Number: NCT05424783 Phase: Not Applicable Trial Summary: The overarching goal is to prospectively recruit men considering active surveillance for treatment in the MAGIC (MRI And GPS Informing Choices for prostate cancer treatment) Cohort – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Northwestern University Acronym: MAGIC

Stereotactic Ablative Radiation Therapy for Prostate Cancer

February 27th, 2024 | Clinical Trials

NCT Number: NCT05668351 Phase: NA Trial Summary: This single arm trial will investigate a novel way to plan and deliver SABR for prostate cancer. Prostate-directed SABR will be high-dose SABR (40 Gy in 5 fractions) with central sparing of the urethr – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Medical University of South […]

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

February 27th, 2024 | Clinical Trials

NCT Number: NCT04396808 Phase: Not Applicable Trial Summary: This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also developing a pragmatic approach for improved GEC cl – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Michigan Rogel Cancer Center Acronym:

Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study

February 27th, 2024 | Clinical Trials

NCT Number: NCT04870515 Phase: Not Applicable Trial Summary: This clinical trial studies the effects of a diet and physical activity intervention on blood measures of lipids and insulin resistance in patients with prostate cancer undergoing – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Fred Hutchinson Cancer Center Acronym:

Pin It on Pinterest